Boston Scientific (NYSE:BSX) Upgraded by UBS Group to “Strong-Buy” Rating

UBS Group upgraded shares of Boston Scientific (NYSE:BSX) to a strong-buy rating in a research note issued to investors on Tuesday,Zacks.com reports.

Several other analysts also recently weighed in on BSX. Stifel Nicolaus set a $60.00 target price on Boston Scientific in a research note on Wednesday. Canaccord Genuity Group cut their price target on Boston Scientific from $71.00 to $70.00 and set a “buy” rating for the company in a report on Monday, June 1st. BTIG Research reduced their price objective on Boston Scientific from $65.00 to $60.00 and set a “buy” rating for the company in a research report on Wednesday. Daiwa Securities Group downgraded shares of Boston Scientific from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 29th. Finally, Evercore set a $65.00 target price on shares of Boston Scientific in a research report on Monday, July 6th. Two analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $78.00.

Boston Scientific Stock Up 0.0%

Boston Scientific stock opened at $46.06 on Tuesday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. Boston Scientific has a fifty-two week low of $42.20 and a fifty-two week high of $109.50. The firm has a fifty day moving average price of $46.57 and a two-hundred day moving average price of $62.73. The firm has a market cap of $68.47 billion, a price-to-earnings ratio of 19.27, a P/E/G ratio of 0.88 and a beta of 0.58.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.83 by $0.03. The company had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.37 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm’s revenue was up 7.5% compared to the same quarter last year. During the same period last year, the business posted $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, analysts forecast that Boston Scientific will post 3.35 earnings per share for the current year.

Boston Scientific declared that its board has approved a stock repurchase plan on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s leadership believes its stock is undervalued.

Insiders Place Their Bets

In other news, Director David C. Habiger acquired 2,250 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The shares were bought at an average price of $55.92 per share, with a total value of $125,820.00. Following the acquisition, the director owned 13,878 shares of the company’s stock, valued at $776,057.76. This trade represents a 19.35% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Cheryl Pegus acquired 1,770 shares of the stock in a transaction dated Wednesday, May 20th. The shares were purchased at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the transaction, the director owned 1,770 shares of the company’s stock, valued at $99,987.30. This trade represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders bought 9,800 shares of company stock worth $554,012. 0.34% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Boston Scientific

Several institutional investors and hedge funds have recently bought and sold shares of the business. Norges Bank bought a new position in shares of Boston Scientific during the 4th quarter worth about $2,199,395,000. Assenagon Asset Management S.A. increased its stake in Boston Scientific by 133.6% in the first quarter. Assenagon Asset Management S.A. now owns 10,057,936 shares of the medical equipment provider’s stock valued at $631,135,000 after acquiring an additional 5,751,760 shares during the period. Janus Henderson Group PLC raised its position in Boston Scientific by 31.0% in the first quarter. Janus Henderson Group PLC now owns 16,497,366 shares of the medical equipment provider’s stock worth $1,035,202,000 after purchasing an additional 3,907,981 shares in the last quarter. Maverick Capital Ltd. bought a new position in Boston Scientific during the fourth quarter worth about $280,735,000. Finally, Arrowstreet Capital Limited Partnership lifted its stake in Boston Scientific by 25.9% during the first quarter. Arrowstreet Capital Limited Partnership now owns 13,891,668 shares of the medical equipment provider’s stock worth $871,702,000 after purchasing an additional 2,856,040 shares during the period. Institutional investors own 89.07% of the company’s stock.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific reported second-quarter adjusted EPS of $0.86, above the $0.83 consensus estimate, while revenue of $5.442 billion exceeded expectations of roughly $5.36 billion. Sales increased 7.5% year over year, led by 8.3% growth in Cardiovascular and strong international performance. Boston Scientific announces results for second quarter 2026
• Positive Sentiment: The company completed a $2 billion accelerated share repurchase program and announced a $1.5 billion investment in MiRus, including an option to acquire its transcatheter aortic valve replacement business. These actions could support long-term growth and per-share results. Boston Scientific Q2 revenue rises to $5.442 billion
• Neutral Sentiment: Boston Scientific is beginning a global restructuring program expected to cost $700 million to $800 million through 2029, with anticipated headcount reductions and potential annual cost savings of about $500 million. Near-term charges may weigh on results, while savings could improve margins later. Boston Scientific expects headcount reductions amid restructuring initiative
• Negative Sentiment: The company reduced full-year 2026 adjusted EPS guidance to $3.28–$3.32 from $3.34–$3.41, below the approximately $3.36 consensus. Third-quarter EPS and revenue guidance also trail analyst expectations.
• Negative Sentiment: Management cited softer-than-expected Watchman demand, unexpected challenges in the heart-implant market and competition affecting the electrophysiology business. The lower outlook overshadowed the quarterly beat and raised concerns about growth execution. Boston Scientific trims annual profit forecast on softer Watchman device demand
• Negative Sentiment: Analysts responded by cutting price targets, including BTIG to $60 from $65, although it maintained a Buy rating. BTIG lowers Boston Scientific price target

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.